Home Cart Sign in  
Chemical Structure| 1100212-66-5 Chemical Structure| 1100212-66-5

Structure of 1100212-66-5

Chemical Structure| 1100212-66-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 1100212-66-5 ]

CAS No. :1100212-66-5
Formula : C8H4BrF3N2
M.W : 265.03
SMILES Code : FC(C1=CC2=C(NN=C2)C(Br)=C1)(F)F
MDL No. :MFCD27939136
InChI Key :KRAPGTPHSWVOAC-UHFFFAOYSA-N
Pubchem ID :57546119

Safety of [ 1100212-66-5 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 1100212-66-5 ] Show Less

Physicochemical Properties

Num. heavy atoms 14
Num. arom. heavy atoms 9
Fraction Csp3 0.12
Num. rotatable bonds 1
Num. H-bond acceptors 4.0
Num. H-bond donors 1.0
Molar Refractivity 48.8
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

28.68 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.58
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

3.13
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

4.5
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

2.9
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

3.65
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

3.15

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-3.86
Solubility 0.0362 mg/ml ; 0.000137 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-3.4
Solubility 0.105 mg/ml ; 0.000397 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-4.65
Solubility 0.00592 mg/ml ; 0.0000223 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.69 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<0.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.68

Application In Synthesis of [ 1100212-66-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 1100212-66-5 ]

[ 1100212-66-5 ] Synthesis Path-Downstream   1~2

  • 1
  • [ 1100212-66-5 ]
  • [ 68-12-2 ]
  • [ 1100212-67-6 ]
YieldReaction ConditionsOperation in experiment
72% To a solution of <strong>[1100212-66-5]7-bromo-5-(trifluoromethyl)-1H-indazole</strong> (9.05 g, 34.1 mmol) in tetrahydrofuran (120 mL) at 0 C. was added sodium hydride (0.901 g, 37.6 mmol). The ice bath was removed and stirring continued for 20 min. The solution was cooled to -78 C. and treated with tert-butyllithium (1.7 M in pentane, 41.2 mL, 70 mmol) dropwise. The reaction was stirred at -78 C. for 10 min, allowed to warm gradually in the dewar to -50 C., recooled to -78 C., and then treated with dimethylformamide (10.6 mL, 137 mmol). After 15 min, the ice bath was removed and stirring continued for 1 h. The reaction was poured onto ice/1 M hydrochloric acid (120 mL). The mixture was extracted with ethyl acetate (2×). The organics were washed with water, then brine, dried over magnesium sulfate, and concentrated to give a dark solid. The solid was triturated with a minimum of diethyl ether and filtered to give 5.25 g (72%) as a tan solid. 1H-NMR (CDCl3, 500 MHz) delta 10.17 (s, 1H), 8.33 (s, 1H), 8.26 (s, 1H), 8.08 (s, 1H), 2.90 (s, 1H); 13C-NMR (CDCl3, 126 MHz) delta 191.4, 137.2, 135.8, 129.7, 125.8, 124.2, 124.0 (q, J=272 Hz), 123.7 (q, J=34 Hz), 120.6. Mass spec.: 214.93 (MH)-.
  • 2
  • [ 1100212-65-4 ]
  • [ 1100212-66-5 ]
YieldReaction ConditionsOperation in experiment
86% To a suspension of 2-bromo-6-methyl-4-(trifluoromethyl)aniline (1 1.3 g, 44.5 mmol) in hydrochloric acid (8 M, 40 mL, 320 mmol) at -10 C. was added a solution of sodium nitrite (3.22 g, 46.7 mmol) in water (ca. 10 mL) dropwise. After 10 min, the resulting solution was neutralized by addition of solid sodium acetate. The resulting solution was added to a solution of 2-methyl-2-propanethiol (5.01 mL, 44.5 mmol) in ethanol (100 mL) at 0 C. The resulting mixture was stirred at 0 C. for 30 min. The resulting mixture was poured onto ice and the resulting mixture was extracted into diethyl ether (2×). The ethereal was washed with water, then brine, dried over magnesium sulfate, and concentrated. The resulting residue was dissolved in dimethylsulfoxide (25 mL) and transferred to a solution of potassium tert-butoxide (39.9 g, 356 mmol) in dimethylsulfoxide (250 mL) in a cool water bath (ca. 10 C.) via canula. The bath was removed and stirring continued for 30 min. The reaction mixture was poured onto ice/concentrated hydrochloric acid to give a precipitate. After 30 min, the resulting solid was collected by filtration and air dried on the filter overnight to give 10.1 g (86%) as a tan solid. 1H-NMR (CDCl3, 500 MHz) delta 8.24 (s, 1H), 8.01 (s, 1H), 7.73 (s, 1H), 2.83 (bs, 1H); 13C-NMR (CDCl3, 126 MHz) delta 140.7, 136.3, 125.8 (q, J=2.9 Hz), 124.9 (q, J=33 Hz), 123.8 (q, J=273 Hz), 123.2, 118.4 (q, J=3.8 Hz), 104.1.
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 1100212-66-5 ]

Fluorinated Building Blocks

Chemical Structure| 1374258-43-1

A154926 [1374258-43-1]

5-Bromo-7-(trifluoromethyl)-1H-indazole

Similarity: 0.89

Chemical Structure| 1428234-73-4

A179394 [1428234-73-4]

4-Bromo-5-(trifluoromethyl)-1H-indazole

Similarity: 0.88

Chemical Structure| 1000342-95-9

A417797 [1000342-95-9]

4-Bromo-6-(trifluoromethyl)-1H-indazole

Similarity: 0.80

Chemical Structure| 1000341-21-8

A160986 [1000341-21-8]

3-Bromo-6-(trifluoromethyl)-1H-indazole

Similarity: 0.79

Chemical Structure| 885271-64-7

A162590 [885271-64-7]

5-(Trifluoromethyl)-1H-indazole

Similarity: 0.79

Bromides

Chemical Structure| 1374258-43-1

A154926 [1374258-43-1]

5-Bromo-7-(trifluoromethyl)-1H-indazole

Similarity: 0.89

Chemical Structure| 1428234-73-4

A179394 [1428234-73-4]

4-Bromo-5-(trifluoromethyl)-1H-indazole

Similarity: 0.88

Chemical Structure| 885272-97-9

A269903 [885272-97-9]

7-Bromo-5-methyl-1H-indazole

Similarity: 0.83

Chemical Structure| 1257535-45-7

A163851 [1257535-45-7]

7-Bromo-6-methyl-1H-indazole

Similarity: 0.80

Chemical Structure| 953411-10-4

A201681 [953411-10-4]

7-Bromo-1H-indazol-5-amine

Similarity: 0.80

Trifluoromethyls

Chemical Structure| 1374258-43-1

A154926 [1374258-43-1]

5-Bromo-7-(trifluoromethyl)-1H-indazole

Similarity: 0.89

Chemical Structure| 1428234-73-4

A179394 [1428234-73-4]

4-Bromo-5-(trifluoromethyl)-1H-indazole

Similarity: 0.88

Chemical Structure| 1000342-95-9

A417797 [1000342-95-9]

4-Bromo-6-(trifluoromethyl)-1H-indazole

Similarity: 0.80

Chemical Structure| 1000341-21-8

A160986 [1000341-21-8]

3-Bromo-6-(trifluoromethyl)-1H-indazole

Similarity: 0.79

Chemical Structure| 885271-64-7

A162590 [885271-64-7]

5-(Trifluoromethyl)-1H-indazole

Similarity: 0.79

Related Parent Nucleus of
[ 1100212-66-5 ]

Indazoles

Chemical Structure| 1374258-43-1

A154926 [1374258-43-1]

5-Bromo-7-(trifluoromethyl)-1H-indazole

Similarity: 0.89

Chemical Structure| 1428234-73-4

A179394 [1428234-73-4]

4-Bromo-5-(trifluoromethyl)-1H-indazole

Similarity: 0.88

Chemical Structure| 885272-97-9

A269903 [885272-97-9]

7-Bromo-5-methyl-1H-indazole

Similarity: 0.83

Chemical Structure| 1257535-45-7

A163851 [1257535-45-7]

7-Bromo-6-methyl-1H-indazole

Similarity: 0.80

Chemical Structure| 953411-10-4

A201681 [953411-10-4]

7-Bromo-1H-indazol-5-amine

Similarity: 0.80